The research, led by Minglu Li and colleagues at the Department of Hematology of Aerospace Center Hospital in Beijing, set out to build what statisticians call a nomogram — a visual scoring instrument that converts a handful of patient characteristics into a personalized probability estimate. What makes this nomogram distinctive is its statistical engine: rather than treating death from any cause as a single uniform outcome, the team used a competing-risk framework that explicitly accounts for the fact that a patient who relapses and dies of leukemia is no longer at risk of dying from transplant complications. In survival analysis, ignoring such competing events can badly distort risk estimates, inflating apparent mortality rates and muddying clinical decision-making. The Fine-Gray model, the framework the researchers adopted, was developed precisely to handle this subtlety, modeling the cumulative incidence of the event of interest while treating relapse as the competing event.

The study population consisted of 587 patients with high-risk or refractory acute leukemia who underwent their first allogeneic transplant between January 2015 and December 2021 at the single center. To test the model honestly, the team randomly split the cohort into a training set of 411 patients, used to build the model, and a validation set of 176 patients, held back to see how the model performed on data it had never seen. This kind of internal validation is a critical safeguard against overfitting — the statistical sin of building a model that memorizes the quirks of one dataset rather than capturing genuine biological patterns that generalize to new patients.

Selecting which variables to include was itself a methodical process. The researchers turned to least absolute shrinkage and selection operator regression, better known as LASSO, a technique that shrinks the coefficients of weak predictors toward zero and effectively eliminates them, leaving behind only the most informative variables. To ensure the selection was stable rather than a fluke of the particular data, they employed ten-fold cross-validation, repeatedly partitioning the training data so that the variable selection process was tested across many different subsets. Out of this rigorous filtering emerged six predictors of non-relapse mortality: patient age, disease status before transplantation (whether the leukemia was in complete remission or not), the Hematopoietic Cell Transplantation-specific Comorbidity Index score, the time to white blood cell engraftment, the time to platelet engraftment, and the grade of acute graft-versus-host disease.

Each of these predictors tells a clinically meaningful story. Age and comorbidities reflect the body’s baseline resilience going into the procedure — an older patient with significant organ dysfunction simply has less physiological reserve to withstand the assault of conditioning chemotherapy, immune suppression, and potential infections. Pre-transplant disease status matters because patients transplanted in complete remission generally fare better than those transplanted with active, refractory disease. The engraftment timings are particularly interesting because they are early post-transplant events: if the donor’s stem cells take longer than 21 days to produce white blood cells, or longer than 14 days to produce platelets, that sluggish recovery signals a fragile marrow environment associated with higher risk. And acute graft-versus-host disease — the notorious complication in which donor immune cells attack the recipient’s tissues — remains one of the most feared drivers of transplant-related death, so its grade from II to IV carries substantial weight in the model.

The performance numbers are where the tool earns its keep. In the training cohort, the time-dependent area under the receiver operating characteristic curve — a standard measure of how well a model separates those who experience the event from those who do not — reached 0.786 at one year, 0.764 at two years, and 0.746 at three years. In the validation cohort, the model actually performed slightly better, with AUCs of 0.818, 0.799, and 0.806 at the same time points. Values in this range indicate useful, though not perfect, discrimination. The concordance index, a related measure of predictive accuracy for survival data, came in at 0.715 after bootstrap correction in the training set and 0.767 in the validation set, where the 95 percent confidence interval spanned 0.703 to 0.831.

Discrimination alone is not enough, however; a model must also be calibrated, meaning its predicted probabilities should match observed reality. A model that tells every patient they have a 30 percent risk when only 10 percent actually die is discriminating poorly or calibrating poorly, and clinicians acting on such numbers could make harmful decisions. The team assessed calibration using optimism-corrected calibration slopes derived from 200 bootstrap resamples, obtaining values of 0.94, 0.92, and 0.97 at one, two, and three years in the training cohort — figures close to the ideal value of 1.0. In the validation cohort, the slopes of 1.30, 1.14, and 1.16 suggested the model was, if anything, slightly conservative in that patient group, a direction of error that is generally less dangerous than overconfidence.

Perhaps the most practically important result came from the head-to-head comparison with the HCT-CI, the comorbidity index that has long served as a standard pre-transplant risk assessment tool. The new nomogram significantly outperformed it, with a C-index difference of 0.114 (P = 0.020) in the training cohort and 0.191 (P = 0.008) in the validation cohort. The advantage makes intuitive sense: the HCT-CI captures only the patient’s condition before the transplant, whereas the nomogram folds in early post-transplant events like engraftment speed and graft-versus-host disease, which carry fresh, dynamic information about how the transplant is actually unfolding. Decision curve analysis reinforced the point, showing that across clinically relevant threshold probabilities from 5 to 50 percent, the nomogram delivered positive net benefit and consistently beat both the treat-all and treat-none default strategies — meaning that clinicians using the tool to guide decisions would, on average, make better calls than following blanket policies.

The study’s limitations are worth keeping in view. It was a single-center, retrospective analysis, and all 587 patients were treated at one institution in Beijing, so the model’s generalizability to other populations, donor types, and conditioning regimens remains to be demonstrated. External validation on independent cohorts at different centers is the natural next step, and the authors themselves frame the tool as internally validated rather than externally proven. Still, the work represents a meaningful advance in a field where risk prediction has often relied on static, pre-transplant snapshots. By integrating baseline characteristics with the early dynamics of recovery, the nomogram gives clinicians a living risk estimate that can be computed in the crucial weeks after transplantation — precisely the window when interventions such as intensified monitoring, prophylactic treatments, or early escalation of care might tip the balance for the patients who need it most. For the growing population of high-risk and refractory leukemia patients whose only curative option is an allogeneic transplant, turning the black box of non-relapse mortality into a quantifiable, actionable number could ultimately mean the difference between anticipation and reaction.

Subject of Research: A competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in high-risk or refractory acute leukemia

Article Title: Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia

Article References: Li, M., Zhang, W., Zhang, S., Fei, X., Zhao, J., Luo, R., & Wang, J. (2026). Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07294-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07294-5

Keywords: non-relapse mortality, allogeneic hematopoietic stem cell transplantation, acute leukemia, nomogram, competing-risk model, Fine-Gray model, LASSO regression, HCT-CI, graft-versus-host disease, engraftment, risk prediction, hematology

The historical record explains why skepticism took root. Studies conducted in the 1980s and 1990s reported in-hospital mortality approaching 90 percent among patients with acute myeloid leukemia who required invasive mechanical ventilation. Against such figures, many clinicians questioned whether intensive care offered anything more than a prolonged and painful death. Yet the evidence landscape has steadily transformed. Refinements in patient selection, combined with sweeping advances in supportive care, have progressively improved outcomes, and more recent studies report in-ICU mortality rates of approximately 45 percent for critically ill patients with acute leukemia. That trajectory, from near-certain fatality to a coin-flip chance of survival, represents one of the quiet revolutions in hematology and intensive care.

A major new analysis has now brought unprecedented statistical weight to this transformation. An individual participant data meta-analysis by Chean and colleagues, published in Intensive Care Medicine, examines the outcomes of critically ill adults with acute leukemia using data from 2,003 patients treated in 55 intensive care units across 19 countries, with an inclusion period spanning more than two decades, from January 2000 to July 2023. The scale and duration of the study fill a long-standing knowledge gap created by earlier single-center investigations and limited sample-size analyses that focused mainly on patients younger than 60 years, a group that no longer reflects the real-world demographics of the disease.

What distinguishes this meta-analysis methodologically is its use of the individual participant data approach. Unlike conventional meta-analyses that rely on aggregated results extracted from published papers, an IPD meta-analysis goes back to the raw data of each contributing study and reanalyzes them. This allows researchers to improve both the quantity and quality of the evidence, to include information that was never reported in the original publications, and to standardize analyses and outcome definitions across studies. The method demands that investigators contact the corresponding author of every included trial or cohort, an arduous process that explains why such analyses remain relatively rare but carry exceptional authority when completed.

The findings confirm what many specialists hoped but could not previously prove with such rigor: ICU mortality has decreased over time among patients requiring mechanical ventilation. The authors of the accompanying editorial, Guillaume Berton and Norbert Vey of Aix-Marseille University and Institut Paoli-Calmettes in Marseille, attribute this trend to improvements on two fronts simultaneously. On the hematology side, new chemotherapy regimens have emerged, while supportive care has advanced dramatically through antimicrobial prophylaxis and improved management of febrile neutropenia, the dangerous fever that strikes patients whose infection-fighting white cells have been wiped out by both disease and treatment.

Perhaps the most striking demographic shift documented in the analysis is the changing age profile of patients reaching the ICU. The proportion of patients older than 65 years admitted to intensive care nearly doubled over the study period, rising from 18 percent before 2010 to 33 percent after 2010. This is not a coincidence of referral patterns but a direct consequence of therapeutic innovation. For decades, elderly patients with acute leukemia were often offered palliative care because intensive cytotoxic chemotherapy, the gold standard for younger patients, was considered too toxic for bodies with diminished functional reserves. That paradigm has been upended by non-intensive approaches, most notably the combination of hypomethylating agents with the BCL-2 inhibitor venetoclax, which has demonstrated a median overall survival of 14.7 months and has become the standard of care for AML patients ineligible for intensive chemotherapy.

The therapeutic revolution extends further. Although the Chean meta-analysis excluded post-transplant ICU admissions, advances in allogeneic stem-cell transplantation now allow this potentially curative procedure to be offered to increasingly older patients, with evidence supporting matched sibling, unrelated, and haploidentical donor options in those over 60. Together, these developments signal that treatment for older AML patients has moved decisively from palliative approaches to strategies with curative intent, and the resulting lengthening of survival will only reinforce the role of intensive care in this population. But with more therapeutic possibilities come new dilemmas, above all patient selection, which must rest on a careful evaluation of frailty and is tightly interwoven with the triage decisions made before ICU admission is even offered.

The meta-analysis also delivered a finding that unsettles prior assumptions: older age, defined as above 65 years, emerged as an adverse predictor of in-ICU mortality. This contrasts with earlier studies that had reported in-ICU mortality rates for elderly patients similar to those of younger cohorts. The editorial authors suggest the discrepancy may reflect variable levels of expertise among the participating centers, illustrated by differences in outcomes according to the national economic level of the countries involved. Such disparities may influence not only the quality of intensive care management but also which patients are selected for admission in the first place, raising uncomfortable questions about equity of access to critical care for older patients with leukemia.

The stakes of that triage question are amplified by what happens after patients leave the unit. A recent report highlighted in the editorial found that a significant proportion of AML patients require modifications to their antileukemic treatment following ICU discharge, altering their long-term prognosis, with older age increasing this risk. In other words, the ICU episode does not exist in isolation; it can derail the optimal cancer therapy on which survival ultimately depends. Conversely, one important limitation of the Chean analysis is that treatment response was not considered, even though response is a major determinant of survival and of the success of organ failure management. Future studies, the editorial argues, should incorporate modern response criteria, including the residual disease assessments now routinely used in hematology practice.

Finally, the editorial closes with a human dimension that data alone cannot capture: patients’ own wishes. Goals-of-care discussions are key to determining the most appropriate management strategy for critically ill patients with cancer, yet they remain relatively infrequent in practice, a gap that demands further research. Meanwhile, the treatment landscape continues to accelerate. More potent antileukemic agents are inducing deeper and longer responses, but each advance carries novel toxicities: venetoclax can trigger tumor lysis syndrome, targeted molecular therapies against FLT3, IDH, and menin can provoke differentiation syndrome causing respiratory, hemodynamic, and renal failure, and the spread of immunotherapy brings risks exemplified by cytokine release syndrome and immune cell-associated neurotoxicity seen with T-cell engagers and CAR T cells in acute lymphoblastic leukemia. As these therapies expand, the editorial concludes, more than ever a continuous close collaboration between intensivists and hematologists is paramount to ensure proper management of these increasingly complex, increasingly survivable patients.

Subject of Research: Intensive care unit access and outcomes for critically ill adults with acute leukemia

Article Title: Beyond classical boundaries: rethinking ICU access in acute leukemia

Article References: Berton, G., & Vey, N. (2026). Beyond classical boundaries: rethinking ICU access in acute leukemia. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08623-y

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08623-y

Keywords: acute leukemia, intensive care unit, acute myeloid leukemia, ICU mortality, mechanical ventilation, venetoclax, hypomethylating agents, allogeneic stem-cell transplantation, tumor lysis syndrome, individual participant data meta-analysis, elderly patients, goals of care